ВАКЦИНЫ ПРОТИВ ГРИППА: ТЕХНОЛОГИИ, ПРОИЗВОДСТВО, БЕЗОПАСНОСТЬ, БИЗНЕС. УРОКИ ПАНДЕМИИ
Аннотация
Как показала пандемия гриппа 2009 г., ключевыми факторами производства вакцин являются объемы, скорость и безопасность. В мире уделяется пристальное внимание разработке новых универсальных вакцинных препаратов и альтернативных технологических платформ производства гриппозных вакцин для преодоления существующих недостатков. В идеале предприятие по производству вакцин должно быть цикличным и базироваться на ряде производственных и технологических платформ. Пришло время подумать о новой концепции вакцинного производства.
Список ссылок
1. http://www.flu.gov/pandemic/history#. Pandemic flu history.
2. http://www.who.int/csr/resources/publications/swineflu/H1N1Vaccinevirusrecommendation26May2009.pdf. Characteristics of the emergent influenza A (H1N1) viruses and recommendations for vaccine development.
3. http://www.who.int/csr/resources/publications/swineflu/vaccine_virus_development/en/index.htmlStatus of candidate vaccine virus development for the current Influenza A(H1N1) virus.
4. http://www.who.int/csr/resources/publications/swineflu/SAGEH1N1vaccinerecommendation2009_05_19.pdf. Recommendations of the Strategic Advisory Group of Experts (SAGE) on Influenza A (H1N1) vaccines.
5. http://www.cidrap.umn.edu/news-perspective/2010/04/h1n1-lessons-learned-vaccine-production-foiled-confirmed-experts. H1N1 LESSONS LEARNED Vaccine production foiled, confirmed experts' predictions.
6. http://www.cidrap.umn.edu/news-perspective/2009/08/officials-lower-expectations-size-first-novel-flu-vaccine-deliveries. Officials lower expectations for size of first novel flu vaccine deliveries.
7. http://www.who.int/csr/resources/publications/swineflu/safety_results_reassortant_cw_ivr_153.pdf Biocontainment requirements for vaccine production from and quality control of the reassortant candidate vaccine virus IVR-153.9.
8. BioPharm International: Challenges and Trends in Vaccine Manufacturing. S. Ray, October, 2011, 7 P.
9. http://www.cidrap.umn.edu/news-perspective/2010/05/who-pandemic-showed-limits-vaccine-production-capacity. WHO: Pandemic showed limits of vaccine production capacity.
10. http://www.who.int/immunization/topics/influenza/en/index.html. World Health Organization. Influenza. 25 January 2008.
11. http://www.pharmaceuticalengineering.org/pharmaceutical-engineering-magazine/online-exclusives. W. Flaherty, P. Perrone. Environmental and Financial Benefits of Single-Use Technology. 2012.
12. http://www.who.int/csr/resources/publi cations/influenza/CDS_EPR_GIP_2006_1.pdf. World Health Organization (WHO). Global pandemic influenza action to increase vaccine supply. Geneva, Switzerland:WHO Epidemic and Pandemic Alert Response (EPR) Publications; 2006 [cited July 1, 2007].
Список ссылок
1. http://www.flu.gov/pandemic/history#. Pandemic flu history.
2. http://www.who.int/csr/resources/publications/swineflu/H1N1Vaccinevirusrecommendation26May2009.pdf. Characteristics of the emergent influenza A (H1N1) viruses and recommendations for vaccine development.
3. http://www.who.int/csr/resources/publications/swineflu/vaccine_virus_development/en/index.htmlStatus of candidate vaccine virus development for the current Influenza A(H1N1) virus.
4. http://www.who.int/csr/resources/publications/swineflu/SAGEH1N1vaccinerecommendation2009_05_19.pdf. Recommendations of the Strategic Advisory Group of Experts (SAGE) on Influenza A (H1N1) vaccines.
5. http://www.cidrap.umn.edu/news-perspective/2010/04/h1n1-lessons-learned-vaccine-production-foiled-confirmed-experts. H1N1 LESSONS LEARNED Vaccine production foiled, confirmed experts' predictions.
6. http://www.cidrap.umn.edu/news-perspective/2009/08/officials-lower-expectations-size-first-novel-flu-vaccine-deliveries. Officials lower expectations for size of first novel flu vaccine deliveries.
7. http://www.who.int/csr/resources/publications/swineflu/safety_results_reassortant_cw_ivr_153.pdf Biocontainment requirements for vaccine production from and quality control of the reassortant candidate vaccine virus IVR-153.9.
8. BioPharm International: Challenges and Trends in Vaccine Manufacturing. S. Ray, October, 2011, 7 P.
9. http://www.cidrap.umn.edu/news-perspective/2010/05/who-pandemic-showed-limits-vaccine-production-capacity. WHO: Pandemic showed limits of vaccine production capacity.
10. http://www.who.int/immunization/topics/influenza/en/index.html. World Health Organization. Influenza. 25 January 2008.
11. http://www.pharmaceuticalengineering.org/pharmaceutical-engineering-magazine/online-exclusives. W. Flaherty, P. Perrone. Environmental and Financial Benefits of Single-Use Technology. 2012.
12. http://www.who.int/csr/resources/publi cations/influenza/CDS_EPR_GIP_2006_1.pdf. World Health Organization (WHO). Global pandemic influenza action to increase vaccine supply. Geneva, Switzerland:WHO Epidemic and Pandemic Alert Response (EPR) Publications; 2006 [cited July 1, 2007].
Ключевые слова
вакцины, пандемический грипп, одноразовые технологии, бизнес
Ссылки
- Ссылки не определены.
** ** ** ** ** **
ISSN: 2073-8099
** ** ** ** ** **
Подписаться на наши издания Вы можете через почтовые каталоги Объединенный каталог «Пресса России» «Урал Пресс», «Ивис», «Прессинформ» и «Профиздат».
Наши партнеры:
iIPhEB - Международная выставка и форум по фармацевтике и биотехнологиям, 2–4 апреля 2024